|
|
|
|
| LEADER |
02193nam a2200253 u 4500 |
| 001 |
EB002000384 |
| 003 |
EBX01000000000000001163285 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Samson, David J.
|
| 245 |
0 |
0 |
|a Comparative effectiveness and safety of radiotherapy treatments for head and neck cancer
|h Elektronische Ressource
|c prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center ; investigators, David J. Samson, Thomas A. Ratko, Barbara Mauger Rothenberg, Heather M. Brown, Claudia J. Bonnell, Kathleen M. Ziegler, Naomi Aronson
|
| 260 |
|
|
|a Rockville, MD
|b Agency for Healthcare Research and Quality
|c 2010, [2010]
|
| 300 |
|
|
|a 1 PDF file (various pagings)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a United States
|b Agency for Healthcare Research and Quality
|
| 710 |
2 |
|
|a Blue Cross and Blue Shield Association
|b Technology Evaluation Center
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Comparative effectiveness reviews
|
| 500 |
|
|
|a Title from PDF title page. - "May 2010."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK45242
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a This is a comparative effectiveness review of alternative radiation therapy (RT) modalities in the treatment of head and neck cancer including: conventional or two-dimensional (2DRT), three-dimensional conformal (3DCRT), intensity-modulated (IMRT), and proton beam radiotherapy. Key questions that will be addressed are whether any of these modalities is more effective than the others: (1) in reducing normal tissue toxicity and adverse events, and improving quality of life; (2) in improving local tumor control, time to disease progression, and survival; (3) when used in certain anatomic locations or patient subpopulations; and, finally, (4) whether there is more variation in patient outcomes with any modality secondary to user experience, treatment planning, or target volumes
|